Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein - PubMed (original) (raw)
Comparative Study
. 2006 Oct 12;25(47):6262-76.
doi: 10.1038/sj.onc.1209640. Epub 2006 May 15.
Affiliations
- PMID: 16702958
- DOI: 10.1038/sj.onc.1209640
Comparative Study
Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein
T Brummer et al. Oncogene. 2006.
Abstract
The BRAF(V600E) mutation is found in approximately 6% of human cancers and mimics the phosphorylation of the kinase domain activation segment. In wild-type B-Raf (B-Raf(wt)), activation segment phosphorylation is thought to cooperate with negative charges within the N-region for full activation. In contrast to Raf-1, the N-region of B-Raf is constitutively negatively charged owing to the presence of residues D447/D448 and the phosphorylation of S446. Therefore, it has been suggested that this hallmark predisposes B-Raf for oncogenic activation. In this study, we demonstrate that neutralizing mutations of these residues (in particular S446 and S447), or uncoupling of B-Raf from Ras-guanine 5'-triphosphate (GTP), strongly reduce the biological activity of B-Raf in a PC12 cell differentiation assay. We also confirm that S365 is a 14-3-3 binding site, and determine that mutation of this residue rescues the impaired biological activity of B-Raf proteins with a neutralized N-region, suggesting that the N-region opposes a 14-3-3-mediated transition into an inactive conformation. However, in the case of B-Raf(V600E), although complete N-region neutralization resulted in a 2.5-fold reduction in kinase activity in vitro, this oncoprotein strongly induced PC12 differentiation or transformation and epithelial-mesenchymal transition of MCF-10A cells regardless of its N-region charge. Furthermore, the biological activity of B-Raf(V600E) was independent of its ability to bind Ras-GTP. Our analysis identifies important regulatory differences between B-Raf(wt) and B-Raf(V600E) and suggests that B-Raf(V600E) cannot be inhibited by strategies aimed at blocking S446 phosphorylation or Ras activation.
Similar articles
- C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA, DeNicola GM, Winter SP, Tuveson DA. Karreth FA, et al. Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017. Mol Cell. 2009. PMID: 19917255 - B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Cui Y, Guadagno TM. Cui Y, et al. Oncogene. 2008 May 15;27(22):3122-33. doi: 10.1038/sj.onc.1210972. Epub 2007 Dec 10. Oncogene. 2008. PMID: 18071315 - Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
Calleros L, Sánchez-Hernández I, Baquero P, Toro MJ, Chiloeches A. Calleros L, et al. Carcinogenesis. 2009 Oct;30(10):1670-7. doi: 10.1093/carcin/bgp188. Epub 2009 Aug 20. Carcinogenesis. 2009. PMID: 19700418 - BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer.
Ciampi R, Knauf JA, Rabes HM, Fagin JA, Nikiforov YE. Ciampi R, et al. Cell Cycle. 2005 Apr;4(4):547-8. doi: 10.4161/cc.4.4.1631. Epub 2005 Apr 24. Cell Cycle. 2005. PMID: 15753649 Review. - Guilty as charged: B-RAF is a human oncogene.
Garnett MJ, Marais R. Garnett MJ, et al. Cancer Cell. 2004 Oct;6(4):313-9. doi: 10.1016/j.ccr.2004.09.022. Cancer Cell. 2004. PMID: 15488754 Review.
Cited by
- Rethinking the role of oncogenes in papillary thyroid cancer initiation.
Vitale M. Vitale M. Front Endocrinol (Lausanne). 2012 Jun 26;3:83. doi: 10.3389/fendo.2012.00083. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22740838 Free PMC article. No abstract available. - Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
Nucera C, Goldfarb M, Hodin R, Parangi S. Nucera C, et al. Biochim Biophys Acta. 2009 Apr;1795(2):152-61. doi: 10.1016/j.bbcan.2009.01.003. Epub 2009 Jan 31. Biochim Biophys Acta. 2009. PMID: 19356676 Free PMC article. Review. - A novel MCF-10A line allowing conditional oncogene expression in 3D culture.
Herr R, Wöhrle FU, Danke C, Berens C, Brummer T. Herr R, et al. Cell Commun Signal. 2011 Jul 13;9:17. doi: 10.1186/1478-811X-9-17. Cell Commun Signal. 2011. PMID: 21752278 Free PMC article. - Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Shan C, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Fröhling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J. Kang HB, et al. Mol Cell. 2015 Aug 6;59(3):345-358. doi: 10.1016/j.molcel.2015.05.037. Epub 2015 Jul 2. Mol Cell. 2015. PMID: 26145173 Free PMC article. - Reversible control of kinase signaling through chemical-induced dephosphorylation.
Sun Y, Zhou R, Hu J, Feng S, Hu Q. Sun Y, et al. Commun Biol. 2024 Aug 31;7(1):1073. doi: 10.1038/s42003-024-06771-9. Commun Biol. 2024. PMID: 39217250 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous